ClinicalTrials.gg
RecruitingNCT05295615Updated Sep 17, 2026

Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease

An interventional study of ECHS AD Device in Alzheimer Disease, sponsored by Herrick Medical LLC. Recruiting at 1 site in United States. Open to participants aged 50 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Herrick Medical LLC · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
50 Years to 100 Years
Sex
All
01

Study summary

An open label pilot study in mild to moderate AD patients to assess the effects of treatment with ECHS AD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end points are the The Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Mini-Mental State Exam. Participants will be followed-up for 9 months post-treatment.

02

Conditions studied

  • Alzheimer Disease

Browse trials for

03

In context

Alzheimer Disease

3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.

This study's planned enrollment of 40 is below the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Herrick Medical LLC is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 50 years
  2. Patients diagnosed with mild to moderate Alzheimer's Dementia defi
  3. At least an eighth grade of educational achievement
  4. If female, .
  5. score between 16 and 26
  6. Capable of providing consent or having a surrogate (e.g., spouse, family member) capable of providing consent if participant lacks consent capacity
  7. Able and willing to comply with the protocol
  8. If the participant is receiving a cholinesterase inhibitor and/or memantine, such medication has been prescribed for at least 3 months prior to screening and the dose is stable for at least 60 days prior to screening (that dose needs to be maintained throughout the period of this study)
  9. Spouse, family member or professional caregiver agree and are capable of taking care of the participation of the patient in the study (answering questions regarding the patient's condition, assuming responsibility for medication, and applying and supervising the daily PEMF treatments)
  10. Physical clearance for study participation as evaluated by the clinician

Exclusion criteria

Exclusion Criteria:

  1. The patient lacks capacity to consent to study participation and no surrogate is available to provide consent
  2. History of epileptic seizures or epilepsy
  3. Currently taking medication that lowers the seizure threshold
  4. Presence of depression, bipolar disorder, a psychotic disorder, or any other neurological or psychiatric condition (whether now or in the past), which the Investigator finds as interfering with the study
  5. Severe agitation that would interfere with study procedures
  6. Alcoholism or substance use disorder as defined by , Fifth Edition (DSM-5) within last 5 years (addicted more than one year and or in remission less than 3 years) or severe sleep deprivation
  7. Major surgery (defined as any major abdominal, vascular or thoracic surgery requiring general anesthesia and resulting in a period of >1 week hospitalization) within 4 weeks
  8. Head anatomy that interferes with the fit of the treatment device
  9. Participation in another clinical trial within the previous 30 days
  10. Metal implants in the head, (i.e., cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants in mouth
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Active ECHS AD device

    Experimental intervention arm

    Device: ECHS AD Device

Interventions

  • DeviceECHS AD Device

    Pulsed electromagnetic therapy device

06

What researchers measure

Primary outcomes

  1. The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)

    Assessment consisting of 11 tasks, taking up to 30mins, to measure the severity of cognitive dementia symptoms. Score 0-70, Higher number, more severity.

    Time frame: Change between day 0, and 30, 60, 90, 120, 150, 240, 310, 400 days

  2. Mini-Mental Status Exam (MMSE)

    Clinician assessment of cognitive impairment. Scoring 0-30, lower score, more severity

    Time frame: Change between day 0, and 30, 60, 90, 120, 150, 240, 310, 400 days

  3. Global Deterioration questionnaire

    Clinician assessment of cognitive impairment. Scored 0-7, higher score, greater severity

    Time frame: Change between day 0, and 30, 60, 90, 120, 150, 240, 310, 400 days

  4. Quality of Life Scale

    Clinician assessment of cognitive impairment. Scored 0-7, higher score, greater severity

    Time frame: Change between day 0, and 30, 60, 90, 120, 150, 240, 310, 400 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05295615
Lead sponsor
Herrick Medical LLC
Responsible party
Sponsor
First posted
Mar 25, 2022
Start date
May 1, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Manisha Parulekar, MD
Contact
manisha.parulekar@hmhn.org
551-996-1140

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion